ArticleEuropean journal of neurology2026

Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO Trial.

Patrick Vermersch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.